AbbVie: Lymphoma, Mantle-Cell trials
The registry lists 10 Lymphoma, Mantle-Cell studies with AbbVie as lead sponsor. 0 are open to participants now and 5 have results posted.
Phase 1 6Phase 2 5Phase 3 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell LymphomaCompletedNCT04477486Phase 2Results posted
- Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)CompletedNCT03112174Phase 3Results posted
- Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)CompletedNCT01236391Phase 2Results posted
- Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic LeukemiaCompletedNCT01109069Phase 2Results posted
- Study of the Safety and Tolerability of PCI-24781 in Patients With LymphomaCompletedNCT00724984Phase 1/2Results posted
- Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's LymphomaActive, not recruitingNCT06667687Phase 1
- Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell MalignanciesActive, not recruitingNCT05753501Phase 1
- Study to Evaluate Adverse Events, Change in Disease Activity, Movement of Oral ABBV-623 and ABBV-992 Tablets in the Body of Adult Participants With B-cell CancersTerminatedNCT04804254Phase 1
- Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell LymphomaCompletedNCT00849654Phase 1
- A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid MalignanciesCompletedNCT00406809Phase 1/2